Immunoglobulin A (IgA) antibodies against pertussis toxin (PT) and filamentous hemagglutinin (FHA) 
however, of little value for the laboratory diagnosis of pertussis.
Serum antibodies against two protein antigens of Bordetella pertussis, pertussis toxin (PT) and filamentous hemagglutinin (FHA), develop in the great majority of patients with pertussis. Determination of antibodies against these proteins in paired serum samples markedly improves the possibilities of diagnosing the disease (7, 8, 10, 20, 21) . Acellular pertussis vaccines currently undergoing clinical trials contain detoxified PT alone or in combination with FHA, and the serum antibody response after the injection of the two antigens has been studied (2, 3, 9, (11) (12) (13) 17) . Detoxified PT induces protection against disease in humans (1, 4), but it is not yet known if this protection is mediated through a serum antibody response. Animal experiments indicate that FHA is also a protective antigen in animals (15) , but the role of serum antibodies against FHA for protection in humans is not clear. In contrast to this interest in serum antibodies against B. pertussis antigens, little attention has been focused on the development of mucosal antibodies against PT and FHA after disease and vaccination. B. pertussis attaches to the cilia of the human respiratory epithelium but does not invade tissues (14, 19) . It is therefore possible that secretory immunoglobulin A (IgA) is important in protection against infection by blocking attachment. Since infection with pertussis results in long-lasting immunity against reinfection, the first step in evaluating the role of IgA antibodies in protection would be to study the development of secretory PT and FHA antibodies in patients with pertussis. In the present study, we have assayed IgA antibodies against PT and FHA in saliva from patients with pertussis. The possibility of using the determination of antibodies in saliva for the diagnosis of pertussis has also been evaluated.
MATERIALS AND METHODS
Patients. The patients participated in a study of the serum antibody response to PT and FHA (20, 21) There was a wide variation in both anti-FHA and anti-PT titers in saliva from the patients, but some relationship to the duration of symptoms could be discerned. All samples obtained within 5 days after the onset of symptoms lacked detectable antibodies against both PT and FHA. Of the samples obtained 6 to 49 days after the onset of symptoms, 72% (114 of 158) had detectable FHA antibodies, while fewer, only 40% (65 of 161), had detectable PT antibodies (P < 0.001; Z test for comparison of two proportions). Of the samples obtained .50 days after the onset of symptoms, only 1 of 13 lacked detectable antibodies against FHA and 3 of 14 lacked those against PT.
In 62 patients, antibody titers in paired saliva samples obtained at intervals of 2 to 5 weeks could be compared. The geometric mean FHA antibody titers increased from 1/12 to 1/23 (P < 0.001; paired t test). Increases that were fourfold or greater were, however, seen in only 19 patients. The geometric mean PT antibody titers were 1/4.2 for the first saliva sample and 1/5.6 for the second saliva sample (nonsignificant; paired t test). Increases that were fourfold or greater were seen in only 14 patients.
The relationship between the presence or absence of IgA antibodies in saliva and antibodies of one or more classes in serum against PT and FHA in all cases in which saliva and serum had been obtained simultaneously was Of 177 saliva samples tested for the presence of IgA antibodies against both FHA and PT, 63 had antibodies against both antigens and 40 lacked antibodies against both; 64 samples had anti-FHA antibodies but not anti-PT antibodies, and 10 had anti-PT antibodies but not anti-FHA antibodies.
DISCUSSION
Little is known about the importance of mucosal defense factors for protection against B. pertussis infections. Since the organism is not invasive but induces the pathogenic process from colonization of ciliated cells in the respiratory tract (14) , factors which inhibit colonization should be protective. FHA is considered to be of importance for attachment of the organism to ciliated cells (18 IgA antibodies against PT in saliva also developed in many of the patients with pertussis. Like FHA antibodies, PT antibodies were not detected in any saliva sample from patients with a disease duration of 6 days or less. PT antibodies in saliva were detected less often than FHA antibodies in saliva in patients with a disease duration of more than 6 days and also less often in the 30 healthy adults. The absence of IgA antibodies against FHA and PT in saliva samples obtained very early in the disease indicates that mucosal antibodies against these antigens may play a role in defense against infection.
It has been suggested that the determination of IgA antibodies against PT and FHA in saliva (6) could be used for the diagnosis of pertussis. Our results do not agree with this, since only about one-third of the patients had fourfold or greater increases in FHA antibodies and about one-fourth had increases in PT antibodies in saliva. A high titer of FHA antibodies in saliva may also be difficult to interpret as a sign of recent infection, since several healthy adults had high titers of FHA antibodies in saliva even though their known contact with B. pertussis antigens through natural infection or vaccination with whole-cell vaccines had occurred in early childhood. It must be emphasized that several factors other than antibody production must affect the antibody content in a saliva sample; most important of these is the amount of fluid in the saliva, which is dependent on various stimuli of the salivary glands (5).
In conclusion, IgA antibodies against FHA and PT in saliva develop in the majority of patients with pertussis, but the determination of antibodies in saliva is of less diagnostic value than the determination of antibodies in serum.
